Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected thai women enrolled in a phase I safety trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 5, 2012, Pages

  Haaland, Richard E ^a   Chaowanachan, Thanyanan ^a   Evans Strickfaden, Tammy ^a   Van De Wijgert, Janneke H ^b,c   Kilmarx, Peter H ^a   McLean, Catherine A ^a   Hart, Clyde E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; MICROBICIDE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG EFFICACY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SELF REPORT; SEXUAL INTERCOURSE; THAILAND; UTERINE CERVIX CYTOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LAVAGE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME; VAGINA; VIROLOGY; VIRUS LOAD;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; CARRAGEENAN; CROSS-OVER STUDIES; FEMALE; GELS; HIV INFECTIONS; HIV-1; HUMANS; THAILAND; THERAPEUTIC IRRIGATION; TIME FACTORS; VAGINA; VIRAL LOAD;

EID: 84873163190     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318271c8f9     Document Type: Letter

References (13)

1. Skoler-Karpoff S., Ramjee G, Ahmed K., et al Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977-1987.
2. Van Damme L., Govinden R, Mirembe F.M., et al Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359: 463-472.
3. Halpern V, Ogunsola F, Obunge O., et al Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One. 2008;3:e3784.
4. McCormack S, Ramjee G, Kamali A., et al PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329-1337.
5. Abdool Karim Q., Abdool Karim SS, Frohlich JA, et al Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
6. Celum CL. HIV preexposure prophylaxis: new data and potential use. Top Antivir Med. 2011; 19:181-185.
7. Keller MJ, Mesquita PM, Torres N.M., et al Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One. 2010;5: e8781.
8. McLean CA, van de Wijgert JH, Jones HE, et al. HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand. AIDS. 2010;24: 717-722.
9. Whitehead SJ, McLean C, Chaikummao S., et al Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand. PLoS One. 2011;6: e14831.
10. Soedjak HS. Colorimetric micromethod for protein determination with erythrosin B. Anal Biochem. 1994;220:142-148.
11. Brown BK, Darden JM, Tovanabutra S, et al Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol. 2005;79: 6089-6101.
12. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg. 1938;27:493-497.
13. Neurath AR, Strick N, Li YY Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect Dis. 2006;6:150.